New tyrosine kinase inhibitors in the treatment of imatinib resistant GIST: An updated meta-analysis.

110Background: Primary or secondary resistance to Imatinib, convolutes the control of Gastrointestinal Stromal Tumors (GIST). We aimed to evaluate clinical outcomes of new tyrosine kinase inhibitors (TKIs) in the treatment of Imatinib resistant GIST. Methods: Online database search of PubMed, MEDLINE, EMBASE, SCOPUS, COCHRANE, and GOOGLE SCHOLAR was performed (2000– Present); key bibliographies were reviewed. Studies comparing patients with Imatinib resistant GIST who were treated with placebo versus new generation TKIs (Regorafenib, Sunitinib, Nilotinib). Primary outcomes were overall and progression free survival (OS, PFS), secondary outcomes include the most common side effects described in trials using new TKIs. Meta-analysis was conducted using Statistical Analysis System (SAS) software. Relative risks with the corresponding 95% confidence intervals (CI) by random effects models of pooled data were calculated. Study quality was assessed using JADAD scoring system. Results: Out of 16 studies, 4 studie...